Introduction
Aldosterone has been recognized traditionally as one of the mediators regulating homeostasis of water and sodium through mineralocorticoid receptor (MR)-mediated genomic actions on renal tubular cells. However, experimental evidence has recently indicated that MR expression is not confined to renal tissues and that aldosterone directly affects nonepithelial cardiovascular cells. The Randomized Aldactone Evaluation Study (RALES) (1) carried out in 1999 demonstrated highly beneficial effects of an MR antagonist on heart failure. Since then, MR antagonists have also been shown to increase endothelial function (2) and improve the prognosis of myocardial infarction with left ventricular dysfunction or heart failure (3) . These studies suggest a close link between aldosterone and cardiovascular pathophysiology.
Although the classical actions of aldosterone are genomi-cally exerted through MR-mediated transcription, aldosterone also works non-genomically like other steroid hormones (4, 5) . Acute actions of aldosterone have been reported in cells derived from various tissues including renal epithelial cells (6, 7) , cardiac myocytes (8) , endothelial cells (ECs) (9, 10) and vascular smooth muscle cells (VSMCs) (11) . Signaling mechanisms of those nongenomic actions can involve intracellular Ca 2+ ([Ca 2+ ]i), cAMP, protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), Na + -H + transport-linked pH changes, and extracellular signal-regulated kinase (ERK)1/2 depending on the cell type (12, 13) . Schneider et al. (10) , Wehling et al. (14) , and Haseroth et al. (15) observed that aldosterone directly elevates spironolactone-insensitive [Ca 2+ ]i in ECs (10) , VSMCs (14) , and even MR-deficient cells (15) and proposed that such action is mediated by a non-classical MR. In contrast, nongenomically elevated [Ca 2+ ]i by aldosterone in mesenteric arterial cells was reported to be blocked by eplerenone (16) . Liu et al. (9) could not detect any [Ca 2+ ]i changes in VSMCs and found that aldosterone acutely stimulated endothelial NO production that was blocked by an MR antagonist. Studies of the nongenomic actions of aldosterone on vasculature, specifically on rabbit afferent arterioles (17, 18) or human forearm blood flow (19, 20) , have led to inconsistent conclusions as to whether aldosterone is constrictive or dilatory
To provide insight into the nongenomic effects of aldosterone on endothelial function and to clarify the previously reported conflicting results, we examined the effects of aldosterone on nitric oxide (NO) production and [Ca 2+ ]i in cultured ECs as well as on the vascular tone of rat aortic rings.
Methods

Materials
LY294002, L-nitro arginine methyl ester (L-NAME), ATP, dimethylsulfoxide (DMSO), corticosterone, and RU486 were purchased from Sigma-Aldrich Co. (St. Louis, USA). DAF-2 DA and DAF-2 were purchased from Daiichi Pure Chemicals Co. (Tokyo, Japan). Fluo-4 AM and Fura Red AM were purchased from Molecular Probes, Invitrogen Corp. (Carlsbad, USA). Ionomycin was purchased from Calbiochem, EMD Biosciences (La Jolla, USA). Eplerenone was obtained from Pfizer Inc. All other reagents were purchased from Wako Pure Chemical Industries (Osaka, Japan).
Cells
ECs were isolated from bovine fetuses by mechanically scraping the intima of the descending thoracic aorta with a razor and then immediately suspending the sample in M199 (GIBCO, Invitrogen Corp.) supplemented with 20% complement-removed fetal bovine serum (FBS) (JRH Biosciences Inc., Lenexa, USA) and 1% penicillin-streptomycinglutamine (100 ×) (GIBCO, Invitrogen Corp.). These preparations were performed in a slaughterhouse. The cell suspensions were kept in a cool box for 3 to 4 h until the mothers of the fetuses were confirmed to be negative for bovine spongiform encephalopathy (BSE). After centrifugation, cells were resuspended in medium and incubated in a humidified CO2 incubator at 37°C. ECs were passaged before full confluence and used before passage (15) . To eliminate the effects of steroid hormones in the serum, cells were incubated in M199 supplemented with 20% FBS treated with dextran-charcoal for 3-5 d before the experiment.
Nitric Oxide Imaging
ECs seeded on glass-bottomed culture dishes (MatTek Corporation, Ashland, USA) were incubated with 1 × 10 were excited at 488 nm and emissions ranging from 500 to 540 nm were obtained using a Leica confocal laser scanning microscope system (Leica Microsystems, Wetzler, Germany). Images were acquired every 10 s by a built-in program in the confocal system. The processing of ratiometric images was done off-line using the ratio imaging module of OpenLab software (ImproVision Inc., Lexington, USA).
Nitric Oxide Assay
ECs were seeded on 96-well microplates. Following pre-incubation of the cells with either an inhibitor ( 
Western Blotting
ECs were cultured in 6 cm dishes (approximately 3 × min. After ATP (1 × 10 − 5 mol/L) or vehicle was applied to the medium, cells were washed with physiological saline and fixed with 10% trichroloacetic acid for 30 min on ice. Fixed cells were scraped into tubes and centrifuged. Pellets were then dissolved in a urea solution (9 mol/L urea, 2% Triton X-100, 1% dithioerythritol) using sonication. Sodium dodecyl sulfate (SDS) sample buffer was added to the samples, which were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE). The proteins were transferred to a PVDF membrane followed by immunoblotting with anti-endothelial 
Recording of Rat Aortic Ring Tension
Eight-week-old male Sprague-Dawley (SD) rats (approximately 240-280 g) were obtained from Tokyo Laboratory Animals Science Co., Ltd. (Tokyo, Japan). The experimental procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals published by the guidelines of the University of Tokyo Graduate School of Medicine. Rats lightly anesthetized with diethyl ether were sacrificed by collection of whole blood from the abdominal aorta. Then, the thoracic aorta was immediately removed from the body and stripped of connective tissue. In some preparations, the endothelium was mechanically denuded using twisted cotton. The aorta was cut transversally in ring segments with lengths of 4 mm in length. The aortic rings were held between a pair of mandolin wires in 10 mL jacketed organ bath chambers filled with Krebs solution; they were maintained at 37°C and aerated continuously with 95% O2 and 5% CO2. The lower wire of each ring was fixed in place while the upper was suspended from an isometric transducer (TB-651T; Nihon Kohden Corp., Tokyo, Japan). The output signal of the transducer was digitized by a NI USB-6009 device (National Instruments Corporation, Texas, USA).
Fig. 2. Eplerenone and LY294002 inhibit the enhancement of ATP-induced NO production by aldosterone. DAF-2 fluorescence in the culture medium was assayed in the absence (A) or presence (B, C, D, E) of ATP. Enhancement of NO production by treatment with aldosterone (Ald, 1 × 10 −7 mol/L) for 10 min was only significant when cells were stimulated with ATP (A, B). L-
While the rings were equilibrated with a resting force of 1 g for 1 h, the medium was exchanged every 15 min. The rings were then pre-contracted twice by application of KCl (60 mmol/L), which were then washed out each time. After subsequent equilibration for 20 min, the rings were contracted with phenylephrine treatment (1 × 10 − 6 mol/L). After the contractile response reached a plateau, eplerenone (1 × 10 − 5 mol/ L), LY294002 (1 × 10 − 5 mol/L) or vehicle was added to the medium. Vehicle or aldosterone (1 × 10
was then applied for a further 5 min. Five minutes later, cumulative application of acetylcholine (ACh) (3 × 10
− 5 mol/L) was initiated to examine endothelium-dependent reactions. To examine endothelium-independent reactions of the smooth muscle cells, sodium nitroprusside was applied cumulatively (1 × 10
Statistical Analysis
Each experiment was repeated at least three times and values were expressed as mean±SD. 
Results
Enhancement of NO Production by Aldosterone
First, we examined by confocal microscopy whether aldosterone influences NO production in ECs. NO production was monitored by fluorescence of DAF-2, which is a widely used NO indicator. NO production did not increase for at least 20 min immediately after application of aldosterone (1 × 10
mol/L; data not shown), and aldosterone pretreatment did not affect the baseline fluorescence of intracellular DAF-2 ( Fig.  1 , pre-ATP, Ald vs. vehicle). ATP treatment slightly stimulated NO production (Fig. 1, post-ATP, vehicle) . Interestingly, ATP induced remarkably larger increases in the NO production of cells pretreated with 1 × 10 − 7 mol/L aldosterone when compared to those treated with vehicle ( Fig. 1 , post-ATP, Ald vs. vehicle). To quantitatively evaluate the effects of aldosterone, we measured the fluorescence of non-permeable DAF-2 in the culture medium. In the absence of ATP stimulation, pretreatment with 1 × 10 − 7 mol/L aldosterone did not affect NO accumulation,, which was significantly decreased by L-NAME, an eNOS inhibitor ( Fig. 2A ). In contrast, aldosterone enhanced ATP-stimulated increases in NO production (Fig. 2B) , consistent with the imaging data. The enhancement of ATP-stimulated NO production by aldosterone was seen at above 1 × 10 − 7 mol/L (Fig. 2C ). This rapid effect of aldosterone (1 × 10 − 7 mol/L) was blocked by eplerenone, an MR antagonist, and LY294002, a PI3K inhibitor (Fig. 2D) . Notably, longer treatment with aldosterone (20 h) also abolished the enhancement of NO production (Fig.  2D) . Corticosterone, another steroid hormone, enhanced NO production as much as aldosterone. The glucocorticoid receptor (GR) antagonist RU486 almost completely blocked NO enhancement by corticosterone but only partially blocked NO enhancement by aldosterone. These findings suggest that short-term exposure to aldosterone alone does not affect NO production but rather enhances ATP-mediated NO production in ECs by eplerenone-sensitive mechanisms involving PI3K.
Enhanced Phosphorylation of eNOS by Aldosterone
To investigate the mechanisms involved in the enhancement of ATP-stimulated NO production by aldosterone, we next examined eNOS phosphorylation at Ser 1179 by immunoblotting (Fig. 3) . ATP treatment increased phosphorylation of eNOS at Ser 1179 by about 10-fold over the basal level. Although aldosterone alone barely affected the phosphorylation of eNOS Ser 1179 (Ser 1177 for human eNOS), short-term aldosterone exposure significantly enhanced ATP-induced phosphorylation, and this effect was blocked by pre-treatment with eplerenone or LY294002. Treatment with aldosterone for as long as 20 h abolished the enhancement of ATPinduced phosphorylation. The rapid action of aldosterone on ATP-mediated eNOS phosphorylation and its sensitivity to eplerenone and LY294002 agree well with the DAF-2 experiments, suggesting mechanistic links between aldosterone, PI3K, eNOS phosphorylation at Ser 1179 , and enhancement of ATP-induced NO production.
Absence of Effects of Aldosterone on [Ca
2+ ]i
Previous studies have demonstrated nongenomic actions of aldosterone on [Ca 2+ ]i, which is an important regulator of endothelial NO production via binding to calmodulin. Thus, we examined whether aldosterone directly affected [Ca 2+ ]i or modulated ATP-induced [Ca 2+ ]i increases (Fig. 4) . Contrary to previous reports, however, aldosterone alone had no direct effect on [Ca 2+ ]i, which was in agreement with our results showing no direct effect of aldosterone on NO production ( Figs. 1 and 2 ). Subsequent application of ATP and ionomycin rapidly evoked [Ca 2+ ]i increases, but aldosterone did not affect [Ca 2+ ]i dynamics including the initial peaks and subsequent decay phases. Accordingly, the enhancement of ATPinduced NO production by aldosterone did not occur through modulation of ATP-induced changes in [Ca 2+ ]i.
Enhancement of ACh-Induced Vasodilation by Aldosterone
Next, to further confirm the rapid effects of aldosterone on ligand-stimulated NO production, we performed experiments using blood vessels. As expected, brief pre-exposure to aldosterone (1 × 10 respectively. It should be noted that aldosterone alone had no direct effects on the tone of pre-contracted aortas. In accordance with the cell culture experiments (Figs. 1-3) , the enhancement of ACh-induced vasorelaxation by aldosterone was reversed by treatment with eplerenone or LY294002 (Fig. 5C ). In contrast, vasorelaxation by sodium nitroprusside (SNP) was not affected by aldosterone in endotheliumdenuded aortas, suggesting that the enhancement of vasorelaxation by aldosterone occurs through effects on the endothelium (Fig. 5D ).
Discussion Rapid Action of Aldosterone on ECs
We have demonstrated in this study that short-term exposure of ECs or aortic rings to aldosterone enhances NO production and vasorelaxation induced by Ca 2+ -mobilizing agonists. Although previously observed rapid effects of aldosterone on endothelium-dependent blood flow in human forearms were discrepant from our findings even under similar experimental conditions, other previous studies have suggested that aldosterone activates NO production, which counteracts vasoconstrictive stimuli such as high K + (18) and phenylephrine (9) . Here, we have further investigated a different aspect of the vasodilatory role of aldosterone that modifies NO signaling when stimulated by ATP or ACh. Importantly, aldosterone itself could neither mobilize intracellular Ca 2+ nor enhance phosphorylation of eNOS in ECs, and it did not affect the constriction of vascular tone by phenylephrine. By using membrane-targeted FRET-based Ca 2+ sensors (21), we again confirmed that treatment with aldosterone itself caused no specific subplasmalemmal [Ca 2+ ] increase at all (unpublished observation, Mutoh, Isshiki, and Fujita); this finding conflicts with previous reports (10, 22) for unknown reasons.
The speed of the observed activity of aldosterone suggests that it is probably nongenomic, even though aldosterone is thought to activate a classical MR. Rapid actions of aldosterone may occur via classical or non-classical MRs; thus the effects of MR antagonists vary. Haseroth et al. (15) and Michea et al. (16) (Fig. 6, schema) . The sensitivity of cultured ECs to LY294002 is paralleled by the reversal of aldosterone-mediated enhancement of AChinduced vasorelaxation by LY294002, suggesting physiological relevance of the observed rapid PI3K-mediated activity. Further investigations are required to clarify the detailed mechanisms.
Multiple Possible Mechanisms Affecting eNOS Activity
The effect of aldosterone in our study was only seen at higher concentrations (1 × 10 (9) . The wide range of effective concentrations in different models suggests that multiple pathways with different sensitivities to aldosterone affect eNOS regulation; the mechanism selected likely depends on local endothelial conditions or other environmental elements in different tissues. This speculation is supported by the finding that eNOS activation by aldosterone in phenylephrine-contracted aortic rings of normal rats was less clear in spontaneously hypertensive rats (SHR) (9) , whereas the enhancement of ACh-induced vasorelaxation by 1 × 10 − 7 mol/L aldosterone in SD rats was consistently seen even in SHR (unpublished observation, Mutoh, Isshiki, and Fujita). Differences in the experimental redox state may account for some of the discrepancies present between previous findings (13). 
Chronic Effects of Aldosterone on ECs
The time window appears to be critical for the effects of aldosterone on endothelial function. Nagata et al. reported that aldosterone treatment for 16 h impaired eNOS function through decreased levels of the cofactor 5,6,7,8-tetrahydrobiopterin (BH4) (29) . We found that enhancement of ATPinduced eNOS phosphorylation seen after 10 min of treatment with aldosterone disappeared when treatment was extended to 20 h. Thus, chronic administration of aldosterone may cause endothelial dysfunction, presumably as the result of its genomic action through MR. This concept is supported by recent clinical trials demonstrating beneficial cardiovascular effects of MR antagonists in certain populations. It is of great interest to clarify the mechanism underlying the time-sensitive effects of aldosterone on endothelial function and the cardiovascular system.
Physiological Significance
The pathophysiological significance of the nongenomic action of aldosterone is currently unclear. The lowest concentration of aldosterone (1 × 10 − 8 mol/L) that we found effective in our ex vivo experiment was higher than the physiological range, and the possible involvement of the GR cannot be neglected. Corticosterone enhanced NO production, and this effect was completely blocked by RU486, a GR antagonist (Fig. 2E) . Notably, the blockade of aldosterone-mediated NO enhancement by RU486 was only partial, suggesting that at least some effects of aldosterone are exerted independently of GR. In summary, we have shown direct evidence that aldosterone acts acutely on the endothelium as a vasodilator and that it enhances ligand-stimulated NO production by the PI3K pathway but not by generation of increased [Ca 2+ ]i.
Perspectives
Many issues must be further addressed regarding the nongenomic actions of aldosterone, including their association with the development of cardiovascular diseases such as hypertension or chronic heart disease, MR signaling associated with the redox state, aldosterone production in local tissues, and temporal and functional coordination with genomic actions.
The present work provides a new insight into a regulatory system for endothelial function as well as some clues for reconciling the currently conflicting data regarding the rapid effects of aldosterone on the cardiovascular system.
